^
    1d
    Metatypic Carcinoma of the Pancreas: Delineation of a Clinicopathologically Distinct Entity, Characterized by Centrally Necrotic Demarcated High-Grade Carcinoma With Divergent Patterns, Basal Immunophenotype, and Altered Molecular Profile. (PubMed, Am J Surg Pathol)
    It is the first pancreatic carcinoma type in which a basal molecular phenotype can be indicated clinically by both imaging and histopathology, with major potential management implications (as it is also enriched in actionable targets like ARID1A). Recognition of this category is critical for cancer research, as it offers an invaluable group to study plasticity, stroma versatility, necrosis mechanisms, and the basal type in pancreatic cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • GATA6 (GATA Binding Protein 6) • TP63 (Tumor protein 63)
    |
    TP53 mutation • KRAS mutation • KRAS G12D • KRAS G12
    1d
    Computational Screening, ADME Study, and Evaluation of Benzothiazole Derivatives as Potential Anticancer Agents. (PubMed, Med Chem)
    Compounds 12, 17, 27, 43, 45, and 49 demonstrated strong binding affinities and superior pharmacokinetic profiles compared to Gefitinib and Erlotinib. Overall, benzothiazole derivatives represent a promising scaffold for the design of EGFR inhibitors, potentially contributing to targeted anticancer therapy.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    erlotinib • gefitinib
    2d
    A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    2d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    2d
    ReLaPSe: Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Australia and New Zealand Sarcoma Association
    New trial
    2d
    GISTAR-1: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov)
    P2/3, N=255, Not yet recruiting, Ningbo Newbay Technology Development Co., Ltd
    New P2/3 trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT exon 9 mutation
    |
    Stivarga (regorafenib) • NB003
    2d
    Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Zai Lab (Shanghai) Co., Ltd.
    New P1 trial
    2d
    Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma. (PubMed, Cell Death Dis)
    Subsequently, targeting GPL biosynthesis (FSG67) restored DNA-damaging agent (SN-38) sensitivity in SLFN11-deficient EWS model, revealing a potential metabolic vulnerability to overcome chemoresistance. Furthermore, SLFN11 knockout tumors exhibited an elevated phosphocholine/glycerophosphocholine ratio, offering a potential non-invasive diagnostic biomarker.
    Journal
    |
    SLFN11 (Schlafen Family Member 11)
    3d
    Clinical study on the treatment of relapsed/refractory soft tissue sarcoma with liposome irinotecan combined with temozolomide and bevacizumab (ChiCTR2600117731)
    P=N/A, N=24, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Avastin (bevacizumab) • temozolomide
    3d
    Study on Carbon lon lrradiation-lnduced PD-1/PD-L1 Expression in Osteosarcoma and Its Synergistic RadiationImmunotherapy Effects (ChiCTR2600117263)
    P=N/A, N=12, Not yet recruiting, The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center; The Clinical Technology Research And Development Cent
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    3d
    A comparative study on the effectiveness, safety and closure efficiency of through-the-scope twin clip and mantis clip in large mucosal defects of the digestive tract (ChiCTR2600116633)
    P=N/A, N=180, Not yet recruiting, ‌ People's Liberation Army General Hospital Fourth Medical Center; People's Liberation Army General Hospital Fourth Medical Center
    New trial